抗新冠肺炎中药连花清瘟胶囊化学成分与临床功效研究进展 |
投稿时间:2020-11-02 修订日期:2021-05-16 点此下载全文 |
引用本文:曾垣烨,何盈盈,唐庆龙,李康,顾妍秋,陈啸飞.抗新冠肺炎中药连花清瘟胶囊化学成分与临床功效研究进展[J].药学实践杂志,2021,39(4):291~294,361 |
摘要点击次数: 2245 |
全文下载次数: 6283 |
|
基金项目:国家自然科学基金项目(81973275、82003909);上海市科学技术委员会项目(19QA1411500) |
|
中文摘要:新型冠状病毒肺炎(COVID-19)疫情的爆发对人类健康与社会稳定造成了巨大威胁。随着病毒在全球迅速蔓延,针对新型冠状病毒(SARS-CoV-2)的药物开发及其相关研究成为医学领域的迫切问题。COVID-19归入中医学理论中的疫病范畴,连花清瘟胶囊(颗粒)屡次在重大疫情中发挥重要作用。既往研究表明,连花清瘟胶囊可能抑制MERS-CoV、SARS-CoV等多种病毒的生物活性。该文整理了历年国内外有关连花清瘟胶囊相关研究成果,从其化学成分、临床功效以及药理作用等方面进行综述分析,以期对连花清瘟胶囊抗病毒机制研究和新冠肺炎临床治疗提供科学依据。 |
中文关键词:新型冠状病毒肺炎 连花清瘟胶囊 药理活性 |
|
Research progress on chemical composition and clinical efficacy of Lianhua Qingwen (LHQW) capsule, a traditional Chinese medicine (TCM) used to treat COVID-19 |
|
|
Abstract:The outbreak of COVID-19 posed a huge threat to human health and social stability. With the rapid spread of the virus around the world, the drug development and related research of novel coronavirus (SARS-CoV-2) have become an urgent issue in the medical field. COVID-19 fails into the category of epidemics in the theory of TCM. LHQW capsule has repeatedly played an important role in many major epidemics. Previous studies have shown that LHQW capsule can inhibit the biological activity of varied viruses including MERS-CoV and SARS-CoV. The paper summarizes the relevant research data and achievements of LHQW capsule in the past few years, reviews the chemical constituents, clinical efficacy and pharmacological effects of LHQW capsule, and provides scientific basis for the anti-virus mechanism of LHQW capsule and clinical treatment of COVID-19. |
keywords:COVID-19 Lianhua Qingwen capsule pharmacological activity |
查看全文 查看/发表评论 下载PDF阅读器 |
|
关闭 |